Characteristics of nonvalvular AF active cancer patients by anticoagulant use, MarketScan, 2010-2014
| . | Rivaroxaban . | Dabigatran . | Apixaban . | Warfarin . |
|---|---|---|---|---|
| N | 2808 | 2189 | 1078 | 10 021 |
| Age, y | 73.8 ± 10.2 | 74.0 ± 10.3 | 74.9 ± 10.3 | 75.4 ± 10.1 |
| Female, % | 40.7 | 38.3 | 42.5 | 39.4 |
| CHA2DS2-VASc score | 4.0 ± 2.0 | 4.3 ± 2.0 | 4.2 ± 1.9 | 4.6 ± 2.0 |
| Comorbidities, % | ||||
| Hypertension | 82.3 | 83.4 | 85.6 | 85.4 |
| Prior ischemic stroke | 27.4 | 33.9 | 28.8 | 35.6 |
| Metastatic brain lesion | 2 | 1.5 | 1.2 | 2.4 |
| Prior gastrointestinal bleed | 12.1 | 14.4 | 11.6 | 16.6 |
| Prior other bleed | 8 | 10.2 | 7.2 | 13 |
| Liver disease | 9.6 | 10.3 | 9.8 | 11.5 |
| Renal disease | 13.8 | 13.3 | 17.5 | 24.4 |
| Heart failure | 32.4 | 36.3 | 34.6 | 42.5 |
| Medications (pharmacy), % | ||||
| Antiplatelet agents | 2.6 | 3.5 | 4.1 | 3.1 |
| Nonsteroidal anti-inflammatory drugs | 27.3 | 32.6 | 28 | 28.8 |
| Chemotherapy | 21.7 | 18.1 | 16.3 | 23.4 |
| Hormonal therapy | 13.4 | 11.5 | 11.7 | 12.8 |
| Radiation therapy | 12.3 | 10.3 | 8.1 | 11.7 |
| Other cancer therapy/procedures | 65.7 | 69.7 | 71.4 | 64.7 |
| Type of cancer, % | ||||
| Breast | 21.4 | 20.8 | 23.4 | 17.8 |
| Lung | 12.5 | 10.4 | 8.6 | 13.1 |
| Gastrointestinal | 10.3 | 10.7 | 11.6 | 13.9 |
| Genitourinary | 29.0 | 31.3 | 29.8 | 28.7 |
| Gyneco-oncological | 2.6 | 2.2 | 2.0 | 2.5 |
| Hematological | 9.6 | 9.2 | 8.8 | 10.1 |
| Other | 14.6 | 15.4 | 15.8 | 13.9 |
| . | Rivaroxaban . | Dabigatran . | Apixaban . | Warfarin . |
|---|---|---|---|---|
| N | 2808 | 2189 | 1078 | 10 021 |
| Age, y | 73.8 ± 10.2 | 74.0 ± 10.3 | 74.9 ± 10.3 | 75.4 ± 10.1 |
| Female, % | 40.7 | 38.3 | 42.5 | 39.4 |
| CHA2DS2-VASc score | 4.0 ± 2.0 | 4.3 ± 2.0 | 4.2 ± 1.9 | 4.6 ± 2.0 |
| Comorbidities, % | ||||
| Hypertension | 82.3 | 83.4 | 85.6 | 85.4 |
| Prior ischemic stroke | 27.4 | 33.9 | 28.8 | 35.6 |
| Metastatic brain lesion | 2 | 1.5 | 1.2 | 2.4 |
| Prior gastrointestinal bleed | 12.1 | 14.4 | 11.6 | 16.6 |
| Prior other bleed | 8 | 10.2 | 7.2 | 13 |
| Liver disease | 9.6 | 10.3 | 9.8 | 11.5 |
| Renal disease | 13.8 | 13.3 | 17.5 | 24.4 |
| Heart failure | 32.4 | 36.3 | 34.6 | 42.5 |
| Medications (pharmacy), % | ||||
| Antiplatelet agents | 2.6 | 3.5 | 4.1 | 3.1 |
| Nonsteroidal anti-inflammatory drugs | 27.3 | 32.6 | 28 | 28.8 |
| Chemotherapy | 21.7 | 18.1 | 16.3 | 23.4 |
| Hormonal therapy | 13.4 | 11.5 | 11.7 | 12.8 |
| Radiation therapy | 12.3 | 10.3 | 8.1 | 11.7 |
| Other cancer therapy/procedures | 65.7 | 69.7 | 71.4 | 64.7 |
| Type of cancer, % | ||||
| Breast | 21.4 | 20.8 | 23.4 | 17.8 |
| Lung | 12.5 | 10.4 | 8.6 | 13.1 |
| Gastrointestinal | 10.3 | 10.7 | 11.6 | 13.9 |
| Genitourinary | 29.0 | 31.3 | 29.8 | 28.7 |
| Gyneco-oncological | 2.6 | 2.2 | 2.0 | 2.5 |
| Hematological | 9.6 | 9.2 | 8.8 | 10.1 |
| Other | 14.6 | 15.4 | 15.8 | 13.9 |
Values are mean ± standard deviation or percentage. Gastrointestinal malignancies (stomach, esophagus, colon cancer, rectal cancer, pancreatic cancer, hepatocellular carcinoma, small intestine cancer), genitourinary malignancies (prostate cancer, testicular cancer, bladder cancer, kidney cancer, and penile cancer), gyneco-oncological malignancies (cancer of cervix, ovary, and uterus), hematological malignancies (leukemia and lymphomas), and “Other” for any remaining nonmelanoma rare cancers.